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Abstract
Backgroud: Cerebral vasospasm (CVS) and early brain injury remain major causes of morbidity
and mortality after aneurysmal subarachnoid hemorrhage (SAH). Hydroxymethylglutaryl coenzyme
A reductase inhibitors, also known as statins, has the neuroprotective effects and ameliorating CVS
after SAH. This study was designed to explore apoptosis inhibiting effects of atorvastatin and its
potential apoptotic signal pathway after SAH.
Results:  Preserving blood-brain-barrier permeability, decreasing brain edema, increasing
neurological scores and ameliorating cerebral vasospasm were obtained after prophylactic use of
atorvastatin. TUNEL-positive cells were reduced markedly both in basilar artery and in brain
cortex by atorvastatin. Apoptosis-related proteins P53, AIF and Cytochrome C were up-regulated
after SAH, while they were not affected by atorvastatin. In addition, up-regulation of caspase-3 and
caspase-8 after SAH was decreased by atorvastatin treatment both in mRNA and in protein levels.
Conclusion: The neuroprotective effects of atorvastatin after SAH may be related to its inhibition
of caspase-dependent proapoptotic pathway based on the present results.
Background
Aneurysmal subarachnoid hemorrhage (SAH) affects 10
per 100 000 population in the Western world. For survi-
vors of the initial hemorrhage, cerebral vasospasm and
early brain injury are major causes of subsequent morbid-
ity and mortality [1]. Apoptosis has even been demon-
strated taking part into aneurismal formation and post
SAH vasospasm and early brain injury [2,3]. Following
the global ischemia seen with SAH, apoptosis has been
shown to occur in the hippocampus, blood-brain barrier
(BBB), and vasculature with varying degrees of necrosis
[4]. Several apoptotic pathways that are believed to be
involved in SAH, including the death receptor pathway,
caspase-dependent and-independent pathways, and the
mitochondrial pathway [5].
A growing body of clinical and experimental literature
demonstrates that statins have neuroprotective effects on
stroke but the mechanism(s) by which these drugs
improve stroke outcome is still unclear [1]. Increasing evi-
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dences, however, link these effects to their cholesterol-
independent properties since statins reduce vascular
inflammatory responses, ameliorate endothelial function,
and modulate cytokine responses and NOS activity [6].
The putative neuroprotective actions of statins may lead
to functional restoration after SAH. However, the effects
of statins in the SAH paradigm are not well known till
now. In the present study, we investigate whether atorvas-
tatin, when administered prophylactically, can reduce
brain edema formation, cerebral vasospasm, cell death,
and subsequently promote neurological recovery in a rat
model of SAH. Three recognized apoptotic pathways were
examined, the caspase-dependent and caspase-independ-
ent pathways and the mitochondrial pathway. Cyto-
chrome C was chosen to represent the mitochondrial
pathway, apoptosis-inducing factor (AIF) was chosen to
represent the caspase-independent pathway, and caspases
3 and 8 were chosen to represent the caspase-dependent
pathway. P53 was also been determined as it has been
demonstrated playing an orchestrating role in apoptotic
cell death after experimental SAH [7]. By examining these
apoptosis-related proteins, we hoped to provide an over-
view of atorvastatin on apoptotic pathways after SAH.
Results
Physiological data and mortality
No obvious difference in physiological data was found
among groups at baseline. The blood pressure rose
abruptly just after puncture of ICA and decreased to nor-
mal level at about 5 mins (data not shown), which was
consistent with previous report [8] and our previous
results [9]. The mortality at 24 hour was 50.0% (8 of 16)
in SAH + vehicle group, 25.0% (4 of 16) in atorvastatin
treated group, 43.8% (7 of 16) in SAH group and none in
SC group (0 of 8). The reduction in mortality with atorv-
astatin treatment was significant lower than that in vehicle
treated group (P < 0.05). No significant difference was
found in extent of SAH between atorvastatin and DMSO
group at autopsy (P > 0.05).
Cerebral vasospasm
The mean cross-sectional area of BA was 8281 ± 748 μm2
in SAH + atorvastatin rats, versus 5405 ± 493 μm2 in
SAH+DMSO group, 5874 ± 587 μm2 in SAH group and
9012 ± 843 μm2 in SC group (atorvastatin group versus
DMSO group, P < 0.05; ANOVA). The mean wall thick-
ness of BA was 16.50 ± 5.23 μm in SAH+ atorvastatin
group, 28.50 ± 7.24 μm in SAH+DMSO group, 27.13 ±
6.33 μm in SAH group and 14.24 ± 3.21 μm in SC group
(atorvastatin group versus DMSO group, P  < 0.05;
ANOVA).
Neurological scores
The neurological scores of rats in atorvastatin group were
significantly lower (P < 0.05; ANOVA) than that in sham-
operated group at 6 hour after SAH (14.1 ± 2.9 versus 18.0
± 0.4). And atorvastatin did not improve neurological
functions at 6 hour. However, neurological scores were
improved at 24 hour after SAH in the atorvastatin treated
rats, which were closed to the sham operated rats(17.3 ±
3.7 versus 18.0 ± 0.5, P > 0.05).
BBB permeability
In SAH animals, marked extravasation of Evan's blue dye
into all brain regions was observed at 24 hour, especially
in both hemispheres. High values of Evan's blue dye were
obtained in brain stem and cerebellum, although no sta-
tistical significance was observed between the two regions.
Treatment with atorvastatin significantly decreased the
amount of Evan's blue extravasation both in hemispheres
and in brain stem (1.58 ± 0.23 μg/g in atorvastatin group
versus 1.23 ± 0.14 μg/g brain tissue in DMSO group, P <
0.05, ANOVA).
Brain water content
Significant increase in brain water content was detected in
SAH rats at 24 hour compared with that in sham operated
control rats (78.45 ± 3.23% versus 73.02 ± 2.45%, P <
0.05). Water content was decreased significantly by atorv-
astatin as compared with that in DMSO group. (74.12 ±
3.18% versus 78.23 ± 3.02%, P < 0.05).
TUNEL staining and cell death assay
Few TUNEL positive cells were detected in sham operated
animals. At 24 hour after SAH, TUNEL positive cells
appeared both in basilar artery and in basal cortex in SAH
rats. Treatment with atorvastatin produced remarkable
reduction of TUNEL positive staining both in basilar
artery and in brain cortex (Figure 1A–J).
To investigate apoptotic cell death in acute brain injury
after SAH, DNA fragmentation was analyzed with a com-
mercial enzyme immunoassay (cell death assay). In the
SAH group, the cell death assay revealed that DNA frag-
mentation was significantly increased at 24 hour com-
pared with the sham operated rats. DNA fragmentation
was significantly decreased in atorvastatin-treated rats
compared with that in the vehicle-treated rats at the same
time point (Figure 2).
Apoptosis-related proteins expression
Apoptosis-related proteins were examined in hippocam-
pus and basal cortex. Elevated level of cleaved caspase-3,
caspase-8, AIF, P53 and Cytochrome C were observed in
SAH group (P  < 0.05 versus sham operated control
group). While no significant difference was found of bax
and bcl-2 proteins levels between SAH and sham operated
control rats. Atorvastatin reduced the expression of
cleaved caspase-3 and caspase-8 (P < 0.05 versus vehicle
treated rats), but had no obvious influence on expressionBMC Neuroscience 2009, 10:7 http://www.biomedcentral.com/1471-2202/10/7
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TUNEL staining of basilar artery and basal cortex after SAH Figure 1
TUNEL staining of basilar artery and basal cortex after SAH. Few apoptosis cells were observed in sham operated 
control rats (A and F). Increased TUNEL positive staining was observed in SAH+DMSO (B and G) and SAH rats (D and I), 
which was reduced markedly by atorvastatin. (C and H). Scale bar represents 200 μm. Quantitive analysis showed an obvious 
reduction in number of apoptosis cells (number/mm2) by atorvastatin compared with that in the DMSO group. (E and J, P < 
0.01 vs DMSO group).BMC Neuroscience 2009, 10:7 http://www.biomedcentral.com/1471-2202/10/7
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of AIF, P53 and Cytochrome C. Atorvastatin had no statis-
tical effects on both bax and bcl-2 at 24 hour after SAH
(Figure 3, 4, 5).
mRNA expression of caspase-3 and caspase-8
Consistent with the Western blotting results, mRNA
expression of caspase-3 and caspase-8 was increased after
SAH, and it was decreased markedly by atorvastatin treat-
ment at 12 h after SAH (Figure 6).
Discussion
In this study, we demonstrated that the pleiotropic 3-
hydroxyl-3-methyl-glutaryl-coenzyme A (HMG-CoA)
reductase inhibitor, atorvastatin, when administered pro-
phylacticly, ameliorates early brain injury and cerebral
vasospasm after experimental SAH. Inhibition of the cas-
pase-dependent apoptotic pathways, while not other
apoptosis-related proteins, was observed after treated with
atorvastatin. The neuroprotective effects may be involved
in its potential anti-apoptosis mechanisms. Administra-
tion of caspase inhibitors has been found to reduce cas-
pase-3 activation after SAH [5,10]. However, in the
present research, atorvastatin, which is not a direct inhib-
itor of caspase, significantly reduced caspase-3 activation.
It has been documented that P53 plays an orchestrating
role in apoptotic cell death after experimental SAH [7].
Expression of P53 and caspase-3, 8 was decreased by P53
inhibitor, Pifithrin-α, which showed that P53 acting as an
upstream of caspase activation. However, expression of
P53 and other apoptosis-related proteins were not influ-
enced by atorvastatin based on our results. It can be spec-
ulate that, at least in the apoptosis pathway, atorvastatin
has the direct effect on caspase-3. Pleiotropic effects of
statins has been found after SAH, such as increased phos-
phorylation of Akt and endothelial nitric oxide synthase
[11]. However, whether anti-apoptotic effect of atorvasta-
tin via these pathways was not determined in the present
research.
Despite intense research efforts in aneurismal SAH, we
currently possess a very limited understanding of the
underlying mechanisms that result in brain injury [12].
However, a number of studies have recently indicated that
apoptosis may be a major player in the pathogenesis of
secondary brain injury after SAH [13]. As a result, the
apoptotic cascades present a number of potential thera-
peutic opportunities that may ameliorate secondary brain
injury. Experimental data suggest that these cascades
occur very early after initial insult and may be related
directly to physiologic sequela commonly associated with
SAH [13]. In accordance with the previous reports, our
data imply that numbers of TUNEL positive cells are sig-
nificantly increased in SAH rats, while atorvastatin admin-
istered ahead markedly inhibited apoptosis after SAH.
Apoptosis requires activation of caspases, a cascade of
cysteine proteases activated by proteolytic cleavage, which
target key homeostatic and structural proteins, such as
actin and fodrin as well as nuclear proteins like poly
(ADP-ribose) polymerase (PARP), leading to DNA frag-
mentation and cell death. Caspase-3 activation is consid-
ered one of the final steps responsible for apoptosis [10].
Caspase-3 can proteolytically cleave several crucial cellu-
lar proteins inducing the characteristic changes associated
with apoptosis including PARP-1, considered a hallmark
biochemical characteristic of apoptosis. PARP-1 cleavage
facilitates DNA alteration and nuclear disassembly and
ensures the completion of the energy-dependent apop-
totic process. In this study, atorvastatin significantly
reduces the increased caspase-3 protein expression
observed 24 hour after the insult. Although several studies
have shown that statins may cause apoptosis in different
cell lines, including neuronal cells [14,15], our data show
that administration of atorvastatin to rats reduces the cas-
pase-dependent apoptotic signal induced by SAH. In
agreement with our results, it has been recently reported
that another statin, pravastatin, reduces apoptosis in the
hippocampus of adult rats after transient forebrain
ischemia [16]. The reason for the different effect observed
after "in vitro" or "in vivo" exposure to statins is unclear.
One possibility is that statins do not exert a proapoptotic
effect on brain cells "in vivo". This hypothesis is sup-
ported by the observation that caspase-3 activation and
PARP cleavage were reduced in simvastatin-treated con-
trol animals or in the contralateral side of simvastatin-
treated ischemic animals [17]. Another possibility is that
the pro-apoptotic effect on inflammatory cells and the
inhibition of leucocyte function induced by statins per-
haps overcomes the potential pro-apoptotic effect they
Cell death assay of DNA-fragmentation after SAH Figure 2
Cell death assay of DNA-fragmentation after SAH. 
The results showed that apoptotic-related DNA-fragmenta-
tion was increased significantly in SAH rats compared with 
that in SC rats at 24 hour in basal cortex. Atorvastatin 
decreased the DNA-fragmentation markedly (*, P < 0.05 vs 
DMSO group).BMC Neuroscience 2009, 10:7 http://www.biomedcentral.com/1471-2202/10/7
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Western blot for expression of caspase-3 and caspase-8 Figure 3
Western blot for expression of caspase-3 and caspase-8. Obvious increase of caspase-3 (P17) and caspase-8 (P18) was 
obtained in basal cortex, which was attenuated by atorvastatin. A, Represent expression of caspase-3. B, Represent expression 
of caspase-8. C, Each column represents 5 independent experimental results. (1, Sham operated control; 2, SAH; 3, SAH + 
Atorvastatin; 4, SAH+DMSO *, P < 0.05 vs DMSO group).BMC Neuroscience 2009, 10:7 http://www.biomedcentral.com/1471-2202/10/7
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Represent Western blot for expression of P53 (A), AIF (B), and Cytochrome C (C) in brain cortex Figure 4
Represent Western blot for expression of P53 (A), AIF (B), and Cytochrome C (C) in brain cortex. Obvious 
increase of these apoptosis-related proteins was observed after SAH, while they were not affected by atorvastatin-treatment. 
Each column represents 5 independent experimental results (D). (1, Sham operated control; 2, SAH; 3, SAH+Atorvastatin; 4, 
SAH + DMSO. *, P = ns vs DMSO group).
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might have on neuronal and/or glial cells and the ultimate
result is neuroprotection. Hydroxymethylglutaryl coen-
zyme A reductase inhibitors have an attractive profile for
cerebrovascular research. Statins have been demonstrated
to reduce stroke events independent of their lipid-lower-
ing effect as well as to reduce mortality significantly after
myocardial infarction [18]. We report here that prophy-
lactic treatment with atorvastatin reduces caspase-3 and
Represent Western blot for expression of bax (A) and bcl-2 (B) in brain cortex Figure 5
Represent Western blot for expression of bax (A) and bcl-2 (B) in brain cortex. Bax and bcl-2 proteins expression 
was not changed after SAH, and they were not affected by atorvastatin treatment. C, Each column represents 5 independent 
experimental results. (1, Sham operated control; 2, SAH; 3, SAH+Atorvastatin; 4, SAH+DMSO).BMC Neuroscience 2009, 10:7 http://www.biomedcentral.com/1471-2202/10/7
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caspase-8 expression suggesting that its neuroprotective
effect may result from a reduced number of neurons
undergoing apoptotic cell death. To date, the apoptotic
pathways believed to play a major role in SAH-induced
apoptosis are the death receptor and TNF-a, p53, and the
caspase dependent cascades [19]. However, to the best of
our knowledge, multiple level inhibitors have not been
used. An example of this might be to selectively block the
limiting steps of the caspase independent and -dependent
cascades and the bcl-2 family proteins. But in our present
study, protein levels of bcl-2 and bax expression did not
differ statistically among the three groups, suggesting that
bcl-2 pathway may not participate into the apoptosis
involved in experimental SAH. As to p53, AIF, and Cyto-
chrome C, our data indicated an upregulation of these
apoptosis-related proteins after SAH. However, it was not
affected by atorvastatin, the underlying mechanisms need
further investigation. P53 was thinked as a key molecular
mediated apoptosis after SAH. Inhibition of P53 with
PFTα down-regulated expression of other apoptosis-
related proteins, including caspase-3 and caspase-8 [7]. In
this research, P53 was not inhibited obviously by atorvas-
tatin. This suggested that a unique mechanism of apopto-
sis inhibition underlying in atorvastatin, which made it
more safety for treating SAH than other multi-levels apop-
tosis inhibitors.
Effects of statins on cerebral vasospasm and neurological
outcome after SAH were still controversial [20,21]. Amel-
iorating cerebral vasospasm, improving cerebral autoreg-
ulation, and reducing vasospasm-related DID of statins
were observed in some researches [20]. But based on the
more recent report, statins using was not associated with
less vasospasm and improved outcome after SAH [21].
Difference in enrolled patients, research methods, and
outcome measurement may explain the contradictions.
The contradictions highlighted the importance of basic
study and clinical trials for statins after SAH. As apoptosis
had been observed in hippocampus, blood-brain barrier
(BBB), and vasculature in SAH patients [4], apoptosis
inhibition proved by the present research may be partly
elucidate the effects of long-term neurological improve-
ment of statins. Based on the current research, statins may
be beneficial for SAH treatment due to its effects of amel-
iorating cerebral vasospasm and improving neurological
outcome.
Conclusion
In summary, it appears that cerebral vasospasm and early
brain injury after SAH are combination of physiologic
insults to the brain, resulting in global ischemia, BBB
breakdown, brain edema, and cellular death signaling.
Atorvastatin ameliorated the vasospasm and early brain
injury after experimental SAH. The underlying mecha-
nisms may be related to its inhibition of caspase-depend-
ent proapoptosis pathway.
Methods
The protocol for these experiments was approved by the
special committee on Animal Welfare of Harbin Medical
University and all animals were treated humanely in
accordance with the guidelines for the Care and Use of
laboratory Animals published by the U.S. National Insti-
tutions of Health (NIH Publication No. 85-23, revised
1996).
SAH rat model and grouping
Perforating SAH model was induced as reported previ-
ously with slight modifications [22]. Male Sprague-Daw-
ley rats (300 to 350 g, bought from Harbin Veterinarians
Research Institution) were anesthetized with 2.0% isoflu-
rane in 70% nitrous oxide and 30% oxygen using a face
mask. SAH was confirmed by autopsy in each rat. Animals
that died during surgery were excluded from the experi-
ment. Animals that died after surgery were replaced until
the final group size reached expected number in each
group.
Atorvastatin or same volume of vehicle (dimethyl sulfox-
ide, DMSO) was administered orally by gastric gavage for
15 days before operation. Atorvastatin was dissolved in
1% DMSO and further diluted in physiological buffer
solution (PBS, final 0.01% DMSO). 20 mg·Kg-1·d-1 of
atorvastatin was selected because of stroke prevention
effect was obtained previously in this dose [23]. In sham
operated control (SC) and SAH group (SAH), no treat-
ment was applied.
Mortality and extent of SAH
Mortality was calculated at 24 hour after SAH. The
number of rats used in each group was SAH+atorvastatin
(n = 16), SAH+DMSO (n = 16), SAH (n = 16) and SC (n =
mRNA expression of caspase-3 and caspase-8 Figure 6
mRNA expression of caspase-3 and caspase-8. Con-
sistent with the Western blotting results, mRNA caspase-3 
and caspase-8 was significantly upregulated after SAH. It was 
significantly reduced by atorvastatin. (*, P < 0.05 and **, P < 
0.01 vs DMSO group).BMC Neuroscience 2009, 10:7 http://www.biomedcentral.com/1471-2202/10/7
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8). The animals were sacrificed and autopsied after opera-
tion and extent of SAH was evaluated according to the
method reported by Sugawara et, al [24].
Neurological deficits
Neurological deficits were evaluated at 6 and 24 hour after
SAH using scoring system reported by Garcia et, al. with
slight modifications [25]. The minimum neurological
score is 3 and the maximum is 18. The number of rats
used in each group was SAH+ atorvastatin (n = 8),
SAH+DMSO (n = 8), SAH (n = 6), and SC (n = 6) before
sacrificed. Two independent investigators (LW and SD)
blinded to the grouping took the measurements.
Brain water content
The entire brain was removed at 24 hour and weighed
immediately (wet weight) and again after drying in an
oven at 105°C for 24 hours (dry weight). The percentage
of brain water content was calculated as [(wet weight - dry
weight)/wet weight] × 100%. The number of rats used in
each group was SAH+ torvastatin (n = 5), SAH+DMSO (n
= 5), SAH (n = 5), and SC (n = 5).
BBB permeability
According to the protocol of Uyama et al [26]. and the
extraction method by Rossner and Temple [27], BBB per-
meability was assessed at 24 hour after SAH. Evan's blue
dye (2%; 5 mL/kg) was injected over 2 minutes into the
right femoral vein and allowed to circulate for 60 minutes.
The amount of extravasated Evan's blue dye into the brain
was determined by spectrofluorophotometry. Measure-
ments were conducted at excitation wavelength 620 nm,
emission wave length 680 nm, and bandwidth 10 nm.
The number of animals used in each group was SAH+
atorvastatin (n = 5), SAH+DMSO (n = 5), SAH (n = 5) and
SC (n = 5).
Histological examination and cross-sectional area of BA 
measurement
At 24 hour after SAH, rats were anesthetized and intracar-
dially perfused with PBS followed by 4% paraformalde-
hyde as described previously [4]. Brains were removed
and postfixed in 4% paraformaldehyde for 3 days. Sec-
tions were embedded in paraffin and sliced into 6 μm and
then stained with hematoxylin and eosin (H-E). The
cross-sectional area of basilar artery was calculated as
described by others and our laboratory previously [9,22].
An independent investigator blinded to the grouping took
the measurements. The number of animals used in each
group was SAH+ atorvastatin (n = 5), SAH+DMSO (n = 5),
SAH (n = 5), and SC (n = 5).
TUNEL staining
Brain sections were stained by TUNEL staining Kit (Roche
Inc., Basel, Switzerland), the TUNEL-positive cells were
expressed by fluorescein-dUTP with dNTP or POD with 3-
3' diaminobenzidine (DAB) (manufacturer's protocol for
in situ Apoptosis Detection Kit [Roche Inc.]) as described
previously [13]. A negative control was similarly per-
formed except for omitting TUNEL reaction mixture. Cells
showing nuclear condensation/fragmentation and apop-
totic bodies in the absence of cytoplasmic TUNEL reactiv-
ity, brown staining of nuclei were considered as apoptotic
cells. Apoptotic cells were confirmed with the help of a
pathologist blinded to the grouping. The number of
TUNEL-positive cells in each region was counted in a
high-powered field (× 400) by a investigator who was
blinded to the studies, and expressed as number/mm2.
The number of animals used in each group was SAH+
atorvastatin (n = 5), SAH+DMSO (n = 5), SAH (n = 5),
and SC (n = 5).
Cell death assay
For quantification of DNA fragmentation in brain tissue,
which indicates apoptotic cell death, a commercial
enzyme immunoassay was used to determine cytoplasmic
histone-associated DNA fragments (Roche Molecular Bio-
chemicals, USA). Fresh brain tissue was taken and protein
extraction of the cytosolic fraction was performed as
described [28]. A cytosolic volume containing 50 μg of
protein was used for the enzyme linked immunosorbent
assay, as per the manufacturer's protocol. The number of
animals used in each group was SAH+ atorvastatin group
(n = 5), SAH+DMSO group (n = 5), SAH group (n = 5),
and SC group (n = 5).
Western blotting analysis
The method for Western blot has been described previ-
ously [29]. The samples (20 μg protein) were separated by
sodium dodecyl sulfatepolyacrylamide gel electrophoresis
with 10% polyacrylamide gel. The following primary anti-
bodies were used: goat monoclonal anti-caspase-3 (P17,
1: 1000), goat monoclonal anti-caspase-8 (P18), mouse
monoclonal anti-AIF (1: 1500), rabbit polyclonal anti-
Cytochrome C (1: 1500), rabbit polyclonal anti-Bax, rab-
bit monoclonal anti-Bcl-2, and rabbit polyclonal anti-β-
actin (1: 3000) antibody (Santa Cruz Inc. USA). After
incubation with the primary antibodies, the nitrocellulose
membranes were washed with TBST dilution and incu-
bated with appropriate horseradish peroxidase-labeled
secondary antibodies (1:1000, Santa Cruz Inc. USA) using
1% nonfat milk in TBST for 1 hour at room temperature.
After two rinses and four washes with PBS/Nonidet P-40
or TBST, the membranes were incubated in ECL (Amer-
sham, Little Chalfont, U.K.) reagent for HRP (60s) and
exposure to autoradiography film for visualization of the
bands. The results were quantified by Quantity One Soft-
ware (Biorad). The number of animals used in each group
was SAH+atorvastatin (n = 12), SAH+DMSO (n = 12),
SAH (n = 12), and SC (n = 12).BMC Neuroscience 2009, 10:7 http://www.biomedcentral.com/1471-2202/10/7
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Quantitative Real-time RT-PCR
Total RNA was extracted from brain samples using TrIzol
Regeants (Gibco BRL; Life Technologies, Rockville, MD,
U.S.A) as the manufacture's instructions. As a specific
internal control, the level of glyceraldehyde phosphate
dehydrogenase (GAPDH) was evaluated. To make the
standard curve, serially diluted standard plasmids were
examined. The reaction mixtures contained diluted
cDNA, SYBR Green I Nucleic Acid Stain (Invitrogen Life
Technologies, Carlsbad, CA, USA), 20 μM of each gene
specific primer and nuclease-free water to a final volume
of 50 μl. The PCR reactions were cycled 40 times by a
three-step cycle procedure (denaturation 95°C, 15 s;
annealing 60°C, 1 min; extension 72°C, 1 min) after ini-
tial stages (45°C, 2 min; 95°C, 10 min). All samples were
analyzed in triplicate. The primers were as follows:
Caspase-3: Forward: 5'-TGAGGTGCGGAGCTTGGAAC-3'
Reverse: 5'-GAGTCCATCGACTTGCTTCCATG-3'
Caspase-8:Forward:5'-AGGGGAGCTGTGACTGGCG-3'
Reverse:5'-TGGTCCAAGCACAGGAACTTGA-3'
GAPDH:Forward:5'-CGCCCAGAACATCATCCCT-3'
Reverse:5'-GCACTGTTGAAGTCGCAGGAGA-3'
Statistics
Data were expressed as mean ± S.D. Statistical differences
between atorvastatin and other groups were compared by
one-way ANOVA and then the Tukey-Kramer multiple
comparison procedure, if a significant difference had been
determined by ANOVA. Significance of differences in neu-
rologic scores was analyzed by Kruskal-Wallis one-way
ANOVA followed by multiple comparison procedures
with Dunn's method. Differences in mortality between
groups were tested using Fisher  exact test. Probability
value of P < 0.05 was considered statistically significant.
Abbreviations
SAH: subarachnoid hemorrhage; Atorva: Atorvastatin;
DMSO: dimethyl sulfoxide; SC: sham control; BBB:
blood-brain barrier; AIF: apoptosis inducing factor; H-E:
hematoxylin and eosin; PBS: physiological buffer solu-
tion.
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